drugset / Trial / NCT06838949

A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP

NCT06838949

NaSingle-groupOpen-labelTreatment

Summary

The objective of this study was to evaluate the efficacy and safety of Herombopag in the treatment of elderly patients with ITP.

Timeline

Start
2025-03-03
Primary completion
2026-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject RAFUTROMBOPAG Other / unclassified 5 mg Oral

Indications

No indication recorded.